Stockreport

Gene Therapy Prospects Make Axovant Sciences A Compelling Buy For 2018 [Seeking Alpha]

Axon Enterprise, Inc.  (AXON) 
Last axon enterprise, inc. earnings: 2/7 04:15 pm Check Earnings Report
US:NYSE Investor Relations: investors.axovant.com/investors/sec-filings
PDF Summary Axovant Sciences' ( AXON ) licensing deal with Oxford BioMedica ( OTCPK:OXBDF ) is nothing short of a masterstroke. This deal has opened up the gene the [Read more]